Wednesday, March 22, 2023
HomePress ReleaseEIN PresswireKYAN Therapeutics and Curie Oncology Announce Strategic Collaboration to Provide Personalized Cancer...

KYAN Therapeutics and Curie Oncology Announce Strategic Collaboration to Provide Personalized Cancer Test in Singapore

From left to proper: Dr Toh Chee Keong (Curie Oncology), Hugo Saavedra (KYAN CEO), Masturah Rashid (KYAN Head of R&D) and Bo Hong Tay (Curie Oncology)

KYAN Therapeutics makes use of small knowledge AI in a proprietary phenotypic drug sensitivity assay to information affected person remedy for most cancers sufferers with excessive and unmet wants

SINGAPORE, Could 9, 2022 / — KYAN Therapeutics groups up with Curie Oncology to supply its novel and modern method to actually personalised most cancers remedies. The partnership will begin with the launch of scientific research using KYAN Therapeutics’ proprietary Quadratic Phenotypic Optimization Platform (“QPOP”) for sufferers affected by Colorectal and Gastric cancers. This initiative goals to additional generate knowledge towards providing QPOP as scientific choice help in most cancers care. KYAN Therapeutics plans to launch its business assay in Singapore by the top of 2022.

Conventional commonplace of take care of most cancers is to deal with the situation as an alternative of the affected person although every affected person’s most cancers is exclusive. Solely round 25% of most cancers sufferers profit from this one-size matches all remedy. Most most cancers sufferers nonetheless undergo from the shortage of effectiveness, requiring a number of strains of remedy, and toxicity causes many antagonistic occasions. For some most cancers varieties, response charges are dismal by the third line and clinicians wrestle with the shortage of pointers and scientific knowledge, leaving sufferers with little to no choices.

“Curie Oncology will collaborate with Kyan Therapeutics to determine sufferers appropriate for this new know-how by way of scientific analysis. That is the kind of know-how that we wish to determine to assist advance most cancers take care of our sufferers,” remarks Dr Toh Chee Keong.

Hugo Saavedra, President and CEO of KYAN Therapeutics, says, “Our revolutionary phenotypic response know-how is extremely environment friendly in evaluating mixture therapies towards tumor cells. QPOP ranks 1000’s of doable remedies which can be clinically actionable and actually personalised for every particular person affected person.”

About KYAN Therapeutics

KYAN Therapeutics, Inc. (a Delaware Company headquartered in Singapore) is a biotechnology firm utilizing proprietary and patented know-how to redefine how therapies are developed and provided to sufferers. From preclinical drug improvement to personalised medication, KYAN affords highly effective options with its optimization of drug-dose combos. Utilizing a novel method that employs environment friendly experiments and complicated, small knowledge analytics to drive its computational core, KYAN has recognized protected and efficient therapies in numerous cancers. An assay deployed by KYAN in scientific research has efficiently personalised mixture therapies for over 67 lymphoma sufferers who failed a number of strains of ordinary of care. For extra particulars, please go to:

About Curie Oncology

Curie Oncology is a boutique oncology observe, specialising in complicated oncology. We offer care, in a multi-disciplinary function, that’s particular and personalised. We assist sufferers overcome most cancers and rebuild their lives. Our mission is to maximise each particular person’s likelihood of remedy. Utilizing molecular focused remedies and harnessing the immune system to combat most cancers. We’re guided by precision diagnostics that uncover your most cancers’s distinctive molecular drivers, and its organic potential.

The Curie
KYAN Therapeutics
e mail us right here
Go to us on social media:

Supply hyperlink


Most Popular